Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

Rhea-AI Summary

Clarus Therapeutics Holdings, a pharmaceutical company focused on androgen and metabolic therapies, will release its fourth quarter and full year 2021 financial results on March 30, 2022, after market closure. A conference call is scheduled for the same day at 5:15 p.m. ET, accessible via specific dial-in numbers for domestic and international callers. The details will also be available through their Investors section online. Clarus's first commercial product is JATENZO (testosterone undecanoate), aimed at addressing unmet medical needs.

NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (“Clarus”) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes.

Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the conference call will be accessible through the Investors section of Clarus Therapeutics’ website at Investors.ClarusTherapeutics.com.

About Clarus Therapeutics Holdings, Inc.
Clarus Therapeutics Holdings, Inc. is a pharmaceutical company with expertise in developing androgen and metabolic therapies for men and women – including potential therapies for orphan indications. Clarus Therapeutics’ first commercial product is JATENZO^® (testosterone undecanoate). For more information, visit www.clarustherapeutics.com and www.jatenzo.com. Follow us on Twitter (@Clarus_Thera) and LinkedIn (Clarus Therapeutics).

Clarus Investor Relations Contact:
Kara Stancell
Vice President, Investor Relations & Corporate Communications
kstancell@clarustherapeutics.com
(847) 562-4300 x 206

FAQ

When will Clarus Therapeutics release its Q4 and full year 2021 financial results?

Clarus Therapeutics will release its financial results on March 30, 2022, after the market closes.

What time is the Clarus Therapeutics conference call scheduled?

The conference call is scheduled for March 30, 2022, at 5:15 p.m. ET.

How can I access the Clarus Therapeutics conference call?

You can access the conference call by dialing (844) 249-2007 for domestic calls and (224) 619-3902 for international calls. The conference ID number is 5454819.

What is JATENZO by Clarus Therapeutics?

JATENZO is the first commercial product developed by Clarus Therapeutics, which contains testosterone undecanoate.

What is the stock symbol for Clarus Therapeutics?

The stock symbol for Clarus Therapeutics is CRXT.

Is there a replay available for the Clarus Therapeutics conference call?

Yes, a replay of the conference call will be accessible through the Investors section of Clarus Therapeutics' website.